Clinical Trial Supplier Landscape Market Intelligence

Are you looking for answers on Clinical Trial Supplier Landscape category?

Are you looking for answers on Clinical Trial Supplier Landscape category?

  • What are the key trends in Clinical Trial Supplier Landscape category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Clinical Trial Supplier Landscape industry?
  • How is Clinical Trial Supplier Landscape industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Key Mergers and Acquisitions - Specialists
  • eClinical Supplier Landscape
  • Industry Drivers Driving Structure of CRO Industry

Table of contents

  1. Executive Summary
  1. Clinical Trial Supplier Landscape Market Trends
  1. Clinical Trial Supplier Landscape Buyers’ View
  1. Structural Drivers
  1. Clinical Trial Supplier Landscape Merger and Acquisitions
  1. Clinical Trial Supplier Landscape Industry Talks

Want a more detailed personalised report?

CRO Market Trends

In the past five years, the CRO market has witnessed strong consolidation trends, resulting in a decrease in number of mid-sized, full service CROs. These companies have experienced the slowest annual growth (4 percent annually between 2011 and 2016), whereas small niche or specialty service providers have enjoyed strong relative growth, approaching 10% annually, for the same period.

Change in ownership – Brings more diversity to regular business setup

  • The top four leading CROs - Quintiles, Covance,Parexel, and PPD have each now experienced a change of ownership in the recent past. The owners are strategic partners,well-positioned within the broader health care and life sciences arena, and private equity investors with considerable capital and broad life sciences portfolios. In all these cases,the acquiring companies are not clinical research insiders
  • These buyers see opportunity in re-positioning contract clinical research services.They anticipate operating efficiencies and strategic advantages that can be gained through the increasing use of rich data and sophisticated analytics,as well as the integration of technology solutions and data across the dimensions of project management,study conduct,clinical research,and clinical care

Consolidation brings increase in market share for top 10 CROs

  • Consolidation within the contract clinical research services market during the past five years has been brisk and it has facilitated substantial market share gains among the top 10 largest CROs.

CRO Market Trends

Competition is expected to heat up among integrated service and solution providers. These firms would try to achieve synergies among their integrated portfolio of assets, which would diminish the boundaries between project management and study execution, as well as between clinical research and clinical care.This would bring improvements in data quality,efficiency,performance,and innovation success.

Options for large pharma companies amid consolidation in CRO market space

  • Sponsors now have to choose between a very large CRO or a sub USD 500 million CRO
  • The key for sponsors is to strategically match up the study size and therapeutic area with each CRO selection


  • A small/mid-size CRO may be the right partner for USD 5 million study,but a larger/mega CRO may be an apt partner for USD 25 million program

Future belongs to specialist and large CROs

  • Niche contract service providers will continue to support sponsor company's demand directly and as subcontractors
  • Large full-service CROs will continue to look for ways to differentiate and,in a bold move,some have vertically integrated into the study conduct and patient recruitment arena (e.g., ICON's acquisition of site network PMG Research)
  • The market-leading CROs are well positioned to offer more integrated and creative solutions that will drive innovations in rich data management and analysis and will help accelerate the convergence of clinical research and clinical care

Private equity funded companies are growing dramatically, offering diverse services including oversight, study support, site and patient identification, and selection

  • Several private equity backed companies, including Arsenal Capital's WIRB-Copernicus Group (WCG) and Cinven's Bioclinica, are acquiring and rolling-up clinical research services and technology solutions


  • WCG acquisitions include several major and regional institutional review boards (e.g., WIRB and Copernicus), technology company ePharma Solutions, central review firm MedAvante, and clinical trial enrolment support firm ThreeWire
  • Bioclinica bought Blueprint Clinical and its risk-based monitoring technology solution. Furthermore, it bought patient recruitment provider Medici Group, pharmacovigilance services company Synowledge, and site network Compass Research


Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.


COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)